Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease

被引:109
作者
Stout, Julie C. [1 ]
Jones, Rebecca [2 ]
Labuschagne, Izelle [1 ]
O'Regan, Alison M. [1 ]
Say, Miranda J. [3 ]
Dumas, Eve M. [4 ]
Queller, Sarah [1 ,5 ]
Justo, Damian [6 ,7 ]
Santos, Rachelle Dar [8 ]
Coleman, Allison [8 ]
Hart, Ellen P. [4 ]
Duerr, Alexandra [6 ,7 ]
Leavitt, Blair R. [8 ]
Roos, Raymund A. [4 ]
Langbehn, Doug R. [9 ,10 ]
Tabrizi, Sarah J. [3 ]
Frost, Chris [2 ]
机构
[1] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3800, Australia
[2] Univ London London Sch Hyg & Trop Med, Dept Med Stat, London WC1E 7HT, England
[3] UCL, UCL Inst Neurol, London, England
[4] Leiden Univ, Med Ctr, Dept Neurol, NL-2300 RA Leiden, Netherlands
[5] Queller Consulting, Dunedin, FL USA
[6] Hop La Pitie Salpetriere, APHP, Dept Genet & Cytogenet, Paris, France
[7] Hop La Pitie Salpetriere, APHP, INSERM, UMR S679, Paris, France
[8] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada
[9] Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA
[10] Univ Iowa, Dept Biostat Secondary, Iowa City, IA USA
关键词
CARRIERS; DECLINE; HD;
D O I
10.1136/jnnp-2011-301940
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Deterioration of cognitive functioning is a debilitating symptom in many neurodegenerative diseases, such as Huntington's disease (HD). To date, there are no effective treatments for the cognitive problems associated with HD. Cognitive assessment outcomes will have a central role in the efforts to develop treatments to delay onset or slow the progression of the disease. The TRACK-HD study was designed to build a rational basis for the selection of cognitive outcomes for HD clinical trials. Methods There were a total of 349 participants, including controls (n=116), premanifest HD (n=117) and early HD (n=116). A standardised cognitive assessment battery (including nine cognitive tests comprising 12 outcome measures) was administered at baseline, and at 12 and 24 months, and consisted of a combination of paper and pencil and computerised tasks selected to be sensitive to cortical-striatal damage or HD. Each cognitive outcome was analysed separately using a generalised least squares regression model. Results are expressed as effect sizes to permit comparisons between tasks. Results 10 of the 12 cognitive outcomes showed evidence of deterioration in the early HD group, relative to controls, over 24 months, with greatest sensitivity in Symbol Digit, Circle Tracing direct and indirect, and Stroop word reading. In contrast, there was very little evidence of deterioration in the premanifest HD group relative to controls. Conclusions The findings describe tests that are sensitive to longitudinal cognitive change in HD and elucidate important considerations for selecting cognitive outcomes for clinical trials of compounds aimed at ameliorating cognitive decline in HD.
引用
收藏
页码:687 / 694
页数:8
相关论文
共 50 条
  • [21] Measuring the functional impact of cognitive impairment in Huntington's disease
    Horta-Barba, Andrea
    Martinez-Horta, Sauel
    Perez-Perez, Jesus
    Sampedro, Frederic
    Puig-Davi, Arnau
    Pagonabarraga, Javier
    Kulisevsky, Jaime
    JOURNAL OF NEUROLOGY, 2022, 269 (07) : 3541 - 3549
  • [22] Cognitive training modifies disease symptoms in a mouse model of Huntington's disease
    Yhnell, Emma
    Lelos, Mariah J.
    Dunnett, Stephen B.
    Brooks, Simon P.
    EXPERIMENTAL NEUROLOGY, 2016, 282 : 19 - 26
  • [23] Utility of the Parkinson's disease-Cognitive Rating Scale for the screening of global cognitive status in Huntington's disease
    Martinez-Horta, Saul
    Horta-Barba, Andrea
    Perez-Perez, Jesus
    Sampedro, Frederic
    de Lucia, Natascia
    De Michele, Giuseppe
    Kehrer, Stefanie
    Priller, Josef
    Migliore, Simone
    Squitieri, Ferdinando
    Castaldo, Anna
    Mariotti, Caterina
    Mananes, Veronica
    Luis Lopez-Sendon, Jose
    Rodriguez, Noelia
    Martinez-Descals, Asuncion
    Garcia-Ruiz, Pedro
    Julio, Filipa
    Januario, Cristina
    Delussi, Marianna
    de Tommaso, Marina
    Noguera, Sandra
    Ruiz-Idiago, Jesus
    Sitek, Emilia J.
    Nuzzi, Angela
    Pagonabarraga, Javier
    Kulisevsky, Jaime
    JOURNAL OF NEUROLOGY, 2020, 267 (05) : 1527 - 1535
  • [24] Brain Volumetric Analysis Using Artificial Intelligence Software in Premanifest Huntington's Disease Individuals from a Colombian Caribbean Population
    Rios-Anillo, Margarita R.
    Ahmad, Mostapha
    Acosta-Lopez, Johan E.
    Cervantes-Henriquez, Martha L.
    Henao-Castano, Maria C.
    Morales-Moreno, Maria T.
    Espitia-Almeida, Fabian
    Vargas-Manotas, Jose
    Sanchez-Barros, Cristian
    Pineda, David A.
    Sanchez-Rojas, Manuel
    BIOMEDICINES, 2024, 12 (10)
  • [25] Disease Modelling of Cognitive Outcomes and Biomarkers in the European Prevention of Alzheimer's Dementia Longitudinal Cohort
    Howlett, James
    Hill, Steven M.
    Ritchie, Craig W.
    Tom, Brian D. M.
    FRONTIERS IN BIG DATA, 2021, 4
  • [26] Cognitive Deficits Predict Poorer Functional Capacity in Huntington's Disease: But What Is Being Measured?
    Eddy, Clare M.
    Rickards, Hugh E.
    NEUROPSYCHOLOGY, 2015, 29 (02) : 268 - 273
  • [27] Genetic Risk Underlying Psychiatric and Cognitive Symptoms in Huntington's Disease
    Ellis, Natalie
    Tee, Amelia
    McAllister, Branduff
    Massey, Thomas
    McLauchlan, Duncan
    Stone, Timothy
    Correia, Kevin
    Loupe, Jacob
    Kim, Kyung-Hee
    Barker, Douglas
    Hong, Eun Pyo
    Chao, Michael J.
    Long, Jeffrey D.
    Lucente, Diane
    Vonsattel, Jean Paul G.
    Pinto, Ricardo Mouro
    Abu Elneel, Kawther
    Ramos, Eliana Marisa
    Mysore, Jayalakshmi Srinidhi
    Gillis, Tammy
    Wheeler, Vanessa C.
    Medway, Christopher
    Hall, Lynsey
    Kwak, Seung
    Sampaio, Cristina
    Ciosi, Marc
    Maxwell, Alastair
    Chatzi, Afroditi
    Monckton, Darren G.
    Orth, Michael
    Landwehrmeyer, G. Bernhard
    Paulsen, Jane S.
    Shoulson, Ira
    Myers, Richard H.
    van Duijn, Erik
    Rickards, Hugh
    MacDonald, Marcy E.
    Lee, Jong-min
    Gusella, James F.
    Jones, Lesley
    Holmans, Peter
    BIOLOGICAL PSYCHIATRY, 2020, 87 (09) : 857 - 865
  • [28] Lumbar puncture safety and tolerability in premanifest and manifest Huntington's disease: a multi-analysis cross-sectional study
    Hassan, Yara Refaat
    Rodrigues, Filipe Brogueira
    Zeun, Paul
    Byrne, Lauren M.
    Estevez-Fraga, Carlos
    Tortelli, Rosanna
    Scahill, Rachael, I
    Wild, Edward J.
    Tabrizi, Sarah J.
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [29] Longitudinal cognitive performance of participants with sporadic early onset Alzheimer's disease from LEADS
    Hammers, Dustin B.
    Eloyan, Ani
    Taurone, Alexander
    Thangarajah, Maryanne
    Gao, Sujuan
    Beckett, Laurel
    Polsinelli, Angelina J.
    Kirby, Kala
    Dage, Jeffrey L.
    Nudelman, Kelly
    Aisen, Paul
    Reman, Rema
    La Joie, Renaud
    Lagarde, Julien
    Atri, Alireza
    Clark, David
    Day, Gregory S.
    Duara, Ranjan
    Graff-Radford, Neill R.
    Grant, Ian
    Honig, Lawrence S.
    Johnson, Erik C. B.
    Jones, David T.
    Masdeu, Joseph C.
    Mendez, Mario F.
    Womack, Kyle
    Musiek, Erik
    Onyike, Chiadi U.
    Riddle, Meghan
    Rogalski, Emily
    Salloway, Steven
    Sha, Sharon J.
    Turner, Raymond Scott
    Wingo, Thomas S.
    Wolk, David A.
    Carrillo, Maria C.
    Rabinovici, Gil D.
    Dickerson, Bradford C.
    Apostolova, Liana G.
    LEADS Consortium
    ALZHEIMERS & DEMENTIA, 2025, 21 (02)
  • [30] A clinical classification acknowledging neuropsychiatric and cognitive impairment in Huntington's disease
    Vinther-Jensen, Tua
    Larsen, Ida U.
    Hjermind, Lena E.
    Budtz-Jorgensen, Esben
    Nielsen, Troels T.
    Norremolle, Anne
    Nielsen, Jorgen E.
    Vogel, Asmus
    ORPHANET JOURNAL OF RARE DISEASES, 2014, 9